Brief: ORIC Pharmaceuticals Q4 Net Income USD -36.307 Million
Feb 18 (Reuters) - ORIC Pharmaceuticals Q4 operating expenses USD 39.57 million. * Q4 income from operations USD -39.57 million * Q4 basic EPS USD -0.51 vs. IBES estimate USD -0.51
Recent news on ORIC Pharmaceuticals
See all newsBrief: Oric® Pharmaceuticals Announces Agreement With Cancer Research UK
ORIC Pharmaceuticals Q1 net loss widens on higher R&D costs
Brief: ORIC Pharmaceuticals Q1 Operating Expenses USD 39.619 Million
Brief: Oric Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
ORIC Pharmaceuticals Q4 loss narrows